Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Outlook For Rx: Political Pressure Will Stay, So Will Double-Digit Growth

Executive Summary

Lilly is preparing investors for a prolonged period of pressure on prices and intellectual property - with the reassurance that they can still expect double-digit annual growth from the drug industry

You may also be interested in...



Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay

Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented

Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay

Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented

Rx Pricing Debate Must Be Framed As Trade Issue, Pfizer CEO Says

The pharmaceutical industry needs to re-cast the global pricing and reimportation debate as a trade issue, Pfizer CEO Henry McKinnell told the Bear Stearns conference in New York City Sept. 8

Related Content

UsernamePublicRestriction

Register

PS042430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel